Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1002/adtp.202100059
- Scopus: eid_2-s2.0-85107420922
- WOS: WOS:000659720200001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Inhaled Dry Powder Formulation of Tamibarotene, a Broad‐Spectrum Antiviral against Respiratory Viruses Including SARS‐CoV‐2 and Influenza Virus
Title | Inhaled Dry Powder Formulation of Tamibarotene, a Broad‐Spectrum Antiviral against Respiratory Viruses Including SARS‐CoV‐2 and Influenza Virus |
---|---|
Authors | |
Keywords | Broad-spectrum antiviral drugs Drug repurposing Influenza Pulmonary delivery Severe acute respiratory syndrome coronavirus 2 |
Issue Date | 2021 |
Publisher | John Wiley & Sons Ltd. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2366-3987 |
Citation | Advanced Therapeutics, 2021, v. 4 n. 7, article no. 2100059 How to Cite? |
Abstract | In response to the epidemic and pandemic threats caused by emerging respiratory viral infections, a safe and efficient broad-spectrum antiviral therapy at early onset of infection can significantly improve patients’ outcome. Inhaled dry powder is easy to administer and delivers antiviral agent directly to the primary site of infection, thereby minimizing systemic side effects. Here, spray freeze drying (SFD) technique is employed to formulate tamibarotene, a retinoid derivative with broad-spectrum antiviral activity, as inhalable powder. The SFD tamibarotene powder exhibits desirable physicochemical and aerodynamic properties for inhalation. Pulmonary delivery of tamibarotene powder results in rapid absorption and higher bioavailability compared with intraperitoneal injection of unformulated drug in animals. More importantly, inhalation or intranasal delivery of SFD tamibarotene formulation displays broad-spectrum antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Middle East respiratory syndrome coronavirus, and pandemic 2009 influenza A virus (H1N1) in mouse and hamster models by targeting lower or upper airways, and the efficacy is comparable or superior to the commercially available antivirals remdesivir and zanamivir against specific virus. These results present a promising strategy to combat various respiratory viral infections including SARS-CoV-2 and influenza virus, or even co-infection. |
Persistent Identifier | http://hdl.handle.net/10722/301404 |
ISSN | 2023 Impact Factor: 3.7 2023 SCImago Journal Rankings: 1.063 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Liao, Q | - |
dc.contributor.author | Yuan, S | - |
dc.contributor.author | Cao, J | - |
dc.contributor.author | Tang, K | - |
dc.contributor.author | Qiu, Y | - |
dc.contributor.author | Seow, HC | - |
dc.contributor.author | Man, RCH | - |
dc.contributor.author | Shao, Z | - |
dc.contributor.author | Huang, Y | - |
dc.contributor.author | Liang, R | - |
dc.contributor.author | Chan, JFW | - |
dc.contributor.author | Yuen, KY | - |
dc.contributor.author | Lam, JKW | - |
dc.date.accessioned | 2021-07-27T08:10:33Z | - |
dc.date.available | 2021-07-27T08:10:33Z | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | Advanced Therapeutics, 2021, v. 4 n. 7, article no. 2100059 | - |
dc.identifier.issn | 2366-3987 | - |
dc.identifier.uri | http://hdl.handle.net/10722/301404 | - |
dc.description.abstract | In response to the epidemic and pandemic threats caused by emerging respiratory viral infections, a safe and efficient broad-spectrum antiviral therapy at early onset of infection can significantly improve patients’ outcome. Inhaled dry powder is easy to administer and delivers antiviral agent directly to the primary site of infection, thereby minimizing systemic side effects. Here, spray freeze drying (SFD) technique is employed to formulate tamibarotene, a retinoid derivative with broad-spectrum antiviral activity, as inhalable powder. The SFD tamibarotene powder exhibits desirable physicochemical and aerodynamic properties for inhalation. Pulmonary delivery of tamibarotene powder results in rapid absorption and higher bioavailability compared with intraperitoneal injection of unformulated drug in animals. More importantly, inhalation or intranasal delivery of SFD tamibarotene formulation displays broad-spectrum antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Middle East respiratory syndrome coronavirus, and pandemic 2009 influenza A virus (H1N1) in mouse and hamster models by targeting lower or upper airways, and the efficacy is comparable or superior to the commercially available antivirals remdesivir and zanamivir against specific virus. These results present a promising strategy to combat various respiratory viral infections including SARS-CoV-2 and influenza virus, or even co-infection. | - |
dc.language | eng | - |
dc.publisher | John Wiley & Sons Ltd. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2366-3987 | - |
dc.relation.ispartof | Advanced Therapeutics | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Broad-spectrum antiviral drugs | - |
dc.subject | Drug repurposing | - |
dc.subject | Influenza | - |
dc.subject | Pulmonary delivery | - |
dc.subject | Severe acute respiratory syndrome coronavirus 2 | - |
dc.title | Inhaled Dry Powder Formulation of Tamibarotene, a Broad‐Spectrum Antiviral against Respiratory Viruses Including SARS‐CoV‐2 and Influenza Virus | - |
dc.type | Article | - |
dc.identifier.email | Yuan, S: yuansf@hku.hk | - |
dc.identifier.email | Qiu, Y: qiuysh@hku.hk | - |
dc.identifier.email | Huang, Y: lyqhuang@hku.hk | - |
dc.identifier.email | Chan, JFW: jfwchan@hku.hk | - |
dc.identifier.email | Yuen, KY: kyyuen@hkucc.hku.hk | - |
dc.identifier.email | Lam, JKW: jkwlam@hku.hk | - |
dc.identifier.authority | Yuan, S=rp02640 | - |
dc.identifier.authority | Chan, JFW=rp01736 | - |
dc.identifier.authority | Yuen, KY=rp00366 | - |
dc.identifier.authority | Lam, JKW=rp01346 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1002/adtp.202100059 | - |
dc.identifier.scopus | eid_2-s2.0-85107420922 | - |
dc.identifier.hkuros | 323694 | - |
dc.identifier.volume | 4 | - |
dc.identifier.issue | 7 | - |
dc.identifier.spage | article no. 2100059 | - |
dc.identifier.epage | article no. 2100059 | - |
dc.identifier.isi | WOS:000659720200001 | - |
dc.publisher.place | United Kingdom | - |